Dose escalation schedule: difference between revisions
Diff·revision 21 → 22·16:41, 28 Sep 2025
Difference between revision 21 and revision 22 of Dose escalation schedule. 2 lines changed; the page grew by 311 bytes.
| Revision 21 — 11:41, 8 Sep 2025 UnitAuditUwe (talk) give the concentration in mg/mL as well as in units 4,682 bytes ±0 | Revision 22 — 16:41, 28 Sep 2025 CategoryBot (talk) bot: normalise unit spacing 4,993 bytes +311 | ||
|---|---|---|---|
| 38 | Escalating more slowly, or holding at an intermediate dose, is a recognised approach where tolerability is limiting, and product labelling for several agents permits it explicitly. The cost is that the maintenance dose — and therefore the effect size observed in trials at that dose — is not reached. | 38 | Escalating more slowly, or holding at an intermediate dose, is a recognised approach where tolerability is limiting, and product labelling for several agents permits it explicitly. The cost is that the maintenance dose — and therefore the effect size observed in trials at that dose — is not reached. |
| 39 | 39 | ||
| + | 40 | Restarting after an interruption raises the question of whether adaptation has been lost. Labelling for several products addresses re-escalation after a defined gap, and the gaps specified differ by product. See [[Missed dose]] and [[Prescribing information]]. Nothing here is medical advice.{{r|drucker2018}} | |
| + | 41 | ||
| 40 | == References == | 42 | == References == |
| 41 | {{reflist}} | 43 | {{reflist}} |